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Background: The compounds 1,4-napthoquinone (1,4-NQ), bis-(2,4-dinitrophenyl)sulfide (2,4-DNPS),
4-nitrobenzothiadiazole (4-NBT), 3-dimethylaminopropiophenone (3-DAP) and menadione (MD) were tested for
antimalarial activity against both chloroquine (CQ)-sensitive (D6) and chloroquine (CQ)-resistant (W2) strains of
Plasmodium falciparum through an in vitro assay and also for analysis of non-covalent interactions with P. falciparum
thioredoxin reductase (PfTrxR) through in silico docking studies.
Results: The inhibitors of PfTrxR namely, 1,4-NQ, 4-NBT and MD displayed significant antimalarial activity with IC50
values of < 20 μM and toxicity against 3T3 cell line. 2,4-DNPS was only moderately active. In silico docking analysis
of these compounds with PfTrxR revealed that 2,4-DNPS, 4-NBT and MD interact non-covalently with the intersubunit
region of the enzyme.
Conclusions: In this study, tools for the identification of PfTrxR inhibitors using phenotyphic screening and docking
studies have been validated for their potential use for antimalarial drug discovery project.
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Malaria, a tropical parasitic disease, continues to be the
dominant cause of death in low-income countries especially
in Africa and is considered to be one of the top three
killers among communicable diseases [1]. Malaria caused
by Plasmodium falciparum is considered to be the
most deadly and also the one with highest rate of drug
resistance [2]. Research investment in new and improved
interventions will improve malaria cure, control, increase
the cost-effectiveness of interventions and support efforts
to eliminate malaria [3].
P. falciparum requires efficient antioxidant and
redox systems to prevent damage caused by reactive
oxygen species. In recent years, it has been shown that
P. falciparum (Pf) possesses a functional low molecular
weight thiol thioredoxin (Trx) system [4]. Thioredoxin
reductase (TrxR) is an important enzyme of this redox
system that helps the parasite to maintain an adequate
intracellular redox environment during intraerythrocytic* Correspondence: aic0001@auburn.edu
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distribution, and reproduction in any mediumdevelopment and proliferation. This antioxidant enzyme
(PfTrxR) is essential for the survival of Plasmodium
parasites for combating intraerythrocytic oxidative stress.
Disruption of this enzyme is a feasible way to interfere
with intraerythrocytic development and proliferation
of the malaria parasites [5]. The current chemotherapy
for malaria as recommended by WHO focuses on
artemisinin-based combination therapies (ACTs) as the
front line of treatment for malaria disease. The main
drawbacks of combination therapies are high cost, adverse
drug reactions and a high degree of pharmacokinetic
mismatch between components leading to prolonged
exposure of parasites to low doses of partner drug and
its active metabolites which may facilitate development
of resistant parasites [6].
Development of parasites’ resistance to the known
antimalarials remains a major challenge for the effective
management of malaria. Intensive drug discovery programs
have aimed at developing new antimalarials or modifying
current antimalarials to improve their efficacy and reduce
evidence of resistance.
In silico molecular modeling methods, such as docking
can aid in the drug discovery process by ascertaining the
binding affinities of existing and hypothetical compoundsentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 The five PfTrxR inhibitors.
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Ideally, the simulations can also elucidate the origin
behind the observed inhibition, as crystalline enzyme/
inhibitor complexes of the thioredoxin protein for x-
ray structure determination have not been reported. A
comparison with other disulfide reductases including
glutathione reductases reveals the most common inhibitor
binding sites are at the active site and at the crystallo-
graphic 2-fold axis in the large cavity at the dimer
interface. These sites can be exploited for structure-based
inhibitor development. The dimer interface shows non-
competitive or uncompetitive behavior and their inter-
action with the protein is purely non-covalent [7-10].
Docking calculations are well suited for exploration of
this interface; however, the simulations are unable to
reproduce covalent inhibitors that bind irreversibly at the
active site. A combined experimental and computational
effort may counterbalance this deficiency and provide
an enhanced avenue for inhibitor development.
A comparison between the hTrxR and PfTrxR structures
shows that they have 46% sequence identity and overlay
with an RMSD of 0.91 Å between the 374 monomer atom
pairs. The most important difference that can be exploited
for selective inhibition between the two enzymes is at the
dimer interface. The interface in PfTrxR is narrower than
in hTrxR due to the presence of Tyr101 and His104 and
can therefore host smaller molecules. Their counterparts
in the human isoform are Gln72 and Leu75 and this dif-
ference can determine the chemical nature of suitable in-
hibitors [11]. The molecular surfaces of the parasite and
the human enzymes also indicate that the charges on
the cavity walls are different, with the hTrxR’s being
more negatively charged compared to the PfTrxR’s [11].
The current study is aimed to employ the combined
approach of in silico molecular docking for identifica-
tion of key interactions of PfTrxR inhibitors to improve
selectivity and phenotypic antimalarial assays for identifi-
cation of activity against susceptible and drug-resistant
P. falciparum blood stage cultures to assure the identi-
fication of specific PfTrxR inhibitors as scaffolds for
lead optimization.
Results and discussion
The in vitro antimalarial activity of the five known inhib-
itors of PfTrxR (1,4-NQ, 2,4-DNPS, 4-NBT, 3-DAP, MD)
[12,13] (Figure 1; Table 1) was evaluated against both
CQ-sensitive (D6 clone) and CQ resistant (W2 clone)
strains of P. falciparum, while cell cytotoxicity was
determined against 3T3 cells (Table 1) using the pro-
cedure described earlier. The compounds 1,4-NQ and
4-NBT were found to be the most active against the
two strains of P. falciparum, MD and 2,4-DNPS were
moderately active, and 3-DAP was inactive. In terms of
antiplasmodial activity against the W2 strain, 1,4-NQand 4-NBT showed IC50 value of < 20 μM. The low
correlation between the high PfTrxR inhibitory activity
and moderate antiplasmodial activity of 2,4-DNPS could
be explained by an inability to penetrate the cell mem-
branes. Accordingly, 2,4-DNPS is predicted to have
poor Caco-2 and MDCK cell line permeability. Table 2
gives the computed octanol/water partition coefficient
(logP), solubility in water (logS), polar surface area, and
apparent Caco-2 and MDCK permeability for all com-
pounds given in Figure 1, the enol form of 3-DAP, and CQ.
The lack of antiplasmodial activity of 3-DAP, a Mannich
base, may be due to (i) non-specific alkylation of cellular
thiol groups, and also (ii) due to the absence of active
transport to red blood cells and parasites. The correlation
between inhibition of PfTrxR in the enzyme inhibition
assays and antiplasmodial activity in cell culture allows
for a better evaluation of biological activities of inhibitor
compounds. The active compounds namely, 1,4-NQ, 2,4-
DNPS, 4-NBT and MD showed more toxicity than 3-DAP
against the 3T3 cell line. The 3T3 cells are epithelial cells
that reflect toxicity against proliferating mammalian cells.
In order to test the five PfTrxR inhibitors for their
ability to induce signs of oxidative stress by accelerated
generation and accumulation of reactive oxygen in-
termediates (superoxide radical, hydroxyl radical and
hydrogen peroxide) [15] the intraerythrocytic formation
of ROS was monitored in real-time for 120 min with 2′
7′-dichlorofluorescein diacetate (DCFDA), a fluorescent
ROS probe [16]. Among the compounds tested 4-NBT,
MD and 1,4-NQ caused a significant increase in oxidative
stress (Figure 2). Whereas, 3-DAP and 2,4-DPNS did
not cause the production of ROS. These results suggest
that 4-NBT, MD and 1,4-NQ compromises the capability
of erythrocytes to scavenge reactive oxygen intermediates.
The accumulated intra-erythrocytic oxidative stress by
these compounds may be responsible for the inhibition
of hTrxR enzyme. The erythrocytes, our target cells,
have higher capacity to produce oxidative stress than
3T3 cell line used for cytotoxicity assessment.
Table 1 PfTrxR inhibitory and antiplasmodial activities of tested compounds
Test compounds PfTrxR IC50 (μM)* Pf (D6) CQ sensitive IC50(μM)** SI D6 Pf (W2) CQ resistance IC50(μM)** SI W2 3T3 IC50(μM)
1,4-NQ 0.75 8.9 ± 2.3 4.6 16.7 ± 3.7 2.4 38.5 ± 0.76
2,4-DNPS 0.5 91.2 ± 11.3 0.8 72.3 ± 11.3 1.0 79 ± 3.51
4-NBT 2 8.3 ± 2.1 10 9.8 ± 1.9 8 80 ± 1.15
3-DAP 15.4 >100 >1 >100 >1 >100
MD 1.6 18.5 ± 1.9 3.8 28.3 ± 5.6 2.5 70.5 ± 3.69
CQ 0.055 ± 0.006 0.440 ± 0.045 NC
*IC50 values, preparation of PfTrxR and optimal experimental conditions for the PfTrxR functional assay were reported in Andricopulo et al., 2006 [12]; Charvet
et al., 2003 [13]; Munigunti et al., 2012 [14].
**Values are mean ± S.D. of triplicate observations; SI: Selectivity index. NC: no cytotoxicity up to concentration much higher than the concentration responsible
for its antiplasmodial activity.
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·OH suggest the proficiency in altering intracellular
redox status [17]. The antimalarial naphthoquinones
(1,4-NQ and MD) are believed to perturb the major
redox equilibria of the targeted P. falciparum infected red
blood cells, which might be removed by macrophages.
This perturbation results in development arrest and
death of the malaria parasite at the trophozoite stage [18].
Since these compounds were active against PfTrxR as
well, molecular docking was used to study their interactions
with PfTrxR to gain further insight into the mode of
interaction for these molecules. MD [19], DNPS and 4-
NBT [20] have been proposed to bind at the intersubunit
region in PfTrxR’s. However, 1,4-NQ and 3-DAP bind
to the reductase covalently precluding the use of docking
calculations. For example, 1,4-NQ is an inhibitor of TrxR
that behaves as a subversive substrate [19]. The compound
3-DAP inactivates TrxR by alkylating the C-terminal
redox active catalytic Cys-Cys pair. This is achieved by
the formation of a reactive α, β-unsaturated ketone
intermediate after it undergoes deamination in solution
[13]. Therefore 3-DAP acts an alkylator. The calculations
predict the same activity trend observed in the experimen-
tal IC50 values for the non-covalent inhibitors, 2,4-DNPS,
MD, and 4-NBT in PfTrxR (Table 3).
For the PfTrxR/MD complex, pi stacking interactions
are predicted to form between the inhibitor’s phenyl ringTable 2 Predicted physico-chemical properties of the compou






1,4 NQ 0.486 −0.764 57.
2,4 DNPS 1.406 −3.444 177
4-NBT 0.746 −1.414 75.
3-DAP 1.249 −0.313 32.
3-DAP-enol 1.800 −1.170 25.
MD 0.880 −1.312 55.
CQ 4.276 −3.585 24
Range 95% of drugs (−2.0 / 6.5) (−6.5 / 0.5) (7.0and Tyr101 side chain ring. The backbone nitrogen of
Met105 is in close proximity to the carbonyl group of
MD; however, the predicted angle between N-H and O
of 85° impedes hydrogen bonding. The molecule further
forms hydrophobic interactions with the phenyl ring of
Tyr116′ and the side chains of Ile108 from both sub-
units. Similar to MD, 4-NBT’s phenyl ring also has pi-pi
stacking with Tyr101’s phenyl ring, but forms hydropho-
bic interactions only with Ile108 from subunit B in the
large cavity. The nitro group causes the molecule to
twist subtly compared to MD in order to better interact
with the electrostatic surface created by the peptide
bond between His104 and Met105’s and sulfur (Figure 3).
Compared to the size of the cavity, MD and 4-NBT are
small molecules and do not fully interact with most of
the residues lining the wall of the dimer interface.
2,4-DNPS forms the only electrostatic interaction at a
distance of 3.9 Å with Asn481′. Pi stacking interactions
are formed between one of the inhibitor’s phenyl rings
and Tyr101 side chain ring with the other phenyl ring of
the molecule forming a parallel displaced pi stacking
interaction with Tyr101′ (subunit B). As with MD and
4-NBT, the side chains of Ile108 from both subunits
form hydrophobic interactions with 2,4-DNPS. Most of
the interactions the three molecules are forming with
the proteins are with the intersecting helices between the














/ 330.0) (<25 poor, >500 great) (<25 poor, >500 great)
Figure 2 Formation of reactive oxygen species (ROS), as indicated by increase in fluorescence. DCFDA loaded human erythrocytes by five
PfTrxR inhibitors.
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parasite and human isoform of thioredoxin reductase
(Table 4). The experimental values for 2,4-DNPS show
an 8-fold selectivity for PfTrxR, whereas 4-NBT has a
25-fold selectivity. While the docking simulations correctly
predicted binding trends, limitations in the method,
including potentially inaccurate scoring functions, the
use of rigid proteins, and a lack of solvation could have
contributed to its inability to reproduce the large dif-
ferences observed in the IC50 values.
The docked poses, however, have considerable dif-
ferences within the cavity, which could point to the
observed selectivity (Figure 4). The presence of Tyr101
in PfTrxR enables 2,4-DNPS to form a favorable pi
stacking interaction with the phenyl ring of the mol-
ecule, whereas its counterpart in hTrxR is a Gln72 that
orients the molecule to avoid steric clashes. This results
in the second ring of the molecule forming a parallel dis-
placed pi stacking interaction with Tyr101′, whereas a
hydrogen bond between the nitro group and Gln72’ in the
hTrxR is realized. The effect of this substitution on 4-NBTTable 3 Comparison between computed binding affinities







4-NBT −6.0 2seems to be the fact that the presence of Gln72 pushes the
molecule deep into the large cavity precluding the inter-
action with the residues of the intersecting helices be-
tween the subunits. 1,4-NQ and 4-NBT can be considered
to be attractive leads for further optimization as these
compounds display good PfTrxR inhibitory and antiplas-
modial activity.
A thorough examination of the residues making any
form of interaction with the small molecules showed that
no other, including His104 (PfTrxR) and its counterpart in
hTrxR (Leu75), influences the differences in binding be-
tween the parasite and human isoform. Figure 5 shows
2,4-DNPS docked in both proteins especially showing the
positions of the His104 and Leu75 as an example.
Conclusions
In this study, tools for the identification of PfTrxR inhib-
itors using phenotypic screening and docking studies
have been validated for their potential use for antimal-
arial drug discovery project.
Experimental
Chemicals and enzymes
Deionized water generated by a Milli-Q water system
(Millipore, MA) was used in the experiments. All reagents
were purchased from Sigma–Aldrich.
Biological assays
Antimalarial assay
Briefly, antimalarial activity of the compounds were




Figure 3 The predicted binding poses for the inhibitors
showing the main interactions with the dimer interface
residues. PfTrxR/MD, PfTrxR/4-NBT, and PfTrxR/2, 4-DNPS complexes.
Table 4 Comparison between computed binding affinities




Exptl. IC50(μM) 0.5 4
Calc. binding affinity (kcal/mol) −8.4 −8.1
4-NBT
Exptl. IC50(μM) 2 50
Calc. binding affinity (kcal/mol) −6.0 −5.7
Munigunti et al. Chemistry Central Journal 2013, 7:175 Page 5 of 7
http://journal.chemistrycentral.com/content/7/1/175Leone) and resistant (W2, IndoChina) strains of P. falcip
arum. The 96-well microplate assay is based on the effect
of the compounds on growth of asynchronous cultures
of P. falciparum, as determined by the fluorometric
SYBR green assay [21].
Cytotoxicity assay
Cytotoxicity in terms of cell viability was evaluated using
3T3 cells by AlamarBlue assay [22]. This assay was con-
ducted on compounds designated as active in the PfTrxR
functional assay and the antimalarial phenotypic screening.
ROS assay
Accelerated generation and accumulation of reactive
oxygen intermediates (superoxide radical, hydroxyl radicalFigure 4 The docking pose differences of 2,4-DNPS and 4-NBT
between the Pf- (brown) and h-TrxR (blue). The docked
structures point to the difference in conformation between Try101
(pfTrxR) and Glu72 (hTrxR) which is proposed to have significant
contribution to the observed experimental selectivity.
Figure 5 The predicted binding mode of 2,4-DNPS in the
PfTrxR (beige) and hTrxR (blue) showing the position of the
residues Try101 (PfTrxR) and Glu72 (hTrxR).
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oxidative stress [15]. The intraerythrocytic formation
of ROS was monitored in real-time with 2′7′-dichlor-
ofluorescein diacetate (DCFDA), a fluorescent ROS probe
[16]. Human erythrocytes collected in citrate phosphate
anticoagulant were used. The erythrocytes were washed
twice with 0.9% saline and suspended in PBSG at a
hematocrit of 10%. A 60 mM stock of DCFDA was
prepared in DMSO and added to the erythrocytes sus-
pension in PBSG (10% hematocrit) to obtain the final
concentration of 600 μM. Erythrocytes suspension
containing 600 μM of DCFDA was incubated at 37°C
for 20 min and centrifuged at 1000 g for 5 min. The
pellet of DCFDA loaded erythrocytes was suspended
in PBSG to 50% hematocrit and used for kinetic ROS
formation assay. The assay was directly set up in a
clear flat-bottom 96 well microplate. The reaction
mixture contained 40 μl of DCFDA loaded erythrocytes,
the test compounds (50 μM)) and potassium phosphate
buffer (100 mM, pH 7.4), to make up the final volume
to 200 μl. The controls without drug were also set up
simultaneously. Each assay was set up at least in duplicate.
The plate was immediately placed in a microplate reader
programmed to kinetic measurement of fluorescence
(excitation 488 nm and emission 535 nm) for 2 hours
with 5 min time intervals.
Computational studies
Computational methods
AutoDock Vina [22] was used to dock inhibitors to the
respective targets. Initial Cartesian coordinates for the
protein-ligand structures were derived from reported
crystal structures of hTrxR (PDB ID: 3QFA) [23] and
PfTrxR (PDB ID: 4B1B) [11]. The protein targets were
prepared for molecular docking simulation by removing
water molecules and bound ligands. AutoDockTools
(ADT) [24] was used to prepare the docking simulationswhereas Chimera was used to analyze the docking
poses. All ligands were constructed using PyMol [25]
with subsequent geometry optimizations carried out
using the semi-empirical method PDDG/PM3 [20,26,27].
Polar hydrogens were added. ADME properties logP,
logS, polar surface area, and apparent Caco-2 permeability
for each ligand were computed using QikProp [28,29].
Conjugate gradient minimizations of the systems were
performed using GROMACS [30]. A grid was centered
on the catalytic active site region and included all amino
acid residues within a box size set at x = y = z = 20 Å.
AutoDock Vina details
Standard flexible protocols of AutoDock Vina using the
Iterated Local Search global optimizer [31] algorithm
were used to evaluate the binding affinities of the molecules
and interactions with the receptors. All ligands and
docking site residues, as defined by the box size used
for the receptors, were set to be rotatable. Calculations
were carried out with the exhaustiveness of the global
search set to 100, number of generated binding modes
set to 20 and maximum energy difference between the
best and the worst binding modes set to 5. Following
completion of the docking search, the final compound
pose was located by evaluation of AutoDock Vina’s
empirical scoring function where the conformation with
the lowest docked energy value was chosen as the best.
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